Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced an upcoming poster presentation featuring new clinical data from its Phase 1 clinical study of UPB-101 at the American Thoracic Society (ATS) International Conference, happening May 19-24 in Washington, DC. The poster, co-authored by Aaron Deykin,¹ Chaim M. Brickman,¹ Peter Lloyd,² Oren M. Becker,¹ will be presented on Monday, May 22, 2023, at 11:30am ET. An e-poster will also be made available to conference attendees during the event.

Presentation details:

Presentation Title: A Phase 1 First-in-Human Single Ascending-dose Study With a Novel Antibody to the Human Thymic Stromal Lymphopoietin Receptor

Presenting Author: Aaron Deykin, MD

Poster Number: 682

Session: B31 – Asthma: From Mice to Men, and Back Again

Presentation Date and Time: Monday, May 22, 2023, 11:30am ET

For more information, visit https://conference.thoracic.org/.

About TSLP and TSLPR Blockade

Thymic Stromal Lymphopoietin (TSLP) is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective therapeutic strategy.

TSLP activation is one of the first events in the inflammatory cascade stimulated by allergens, viruses, and other triggers, initiating the upregulation of downstream targets such as IL-4, IL-5, IL-13, IL-17 and IgE. Because TSLP is a target upstream in the inflammatory cascade, there is opportunity to address disease at its root, prior to the influence of other disease-related cytokines. Blocking the TSLP receptor presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases.

About UPB-101

UPB-101 is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to the human thymic stromal lymphopoietin (TSLP) receptor (TSLPR) to inhibit signaling. UPB-101 is designed to address allergic and inflammatory diseases including asthma. In pre-clinical studies, UPB-101 demonstrated inhibition of cytokine production from both CD4+ T cells and ILC2, and completely suppressed skin allergic reactions in a monkey model, suggesting that it may be effective against multiple types of inflammation.

Dosing in the first-in-human Phase 1, randomized, placebo-controlled, single dose-escalation study in healthy volunteers was considered safe and well-tolerated. A follow-on Phase 1b multiple ascending dose study in people diagnosed with asthma is underway.

About Upstream Bio

At Upstream Bio we strive to reach the source of inflammation and conquer it. Our lead program, UPB-101, is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases. We are leveraging our diverse roots and the team’s substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. https://www.upstreambio.com/

_________________________________________________________

¹Upstream Bio, Inc., Waltham, MA, USA

²KinDyn Consulting Ltd., Warnham, England

View source version on businesswire.com: https://www.businesswire.com/news/home/20230512005025/en/